The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRB..L Share News (RB.)

  • There is currently no data for RB.

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Former Indivior CEO pleads guilty in U.S. in opioid addiction treatment probe

Tue, 30th Jun 2020 21:48

(Adds comment from defense lawyer and Indivior)

By Nate Raymond

June 30 (Reuters) - Shaun Thaxter, the former chief
executive of drugmaker Indivior Plc, pleaded guilty on
Tuesday to a criminal charge arising out of a U.S. Justice
Department investigation into the marketing of its opioid
addiction treatment Suboxone.

Thaxter pleaded guilty in federal court in Abingdon,
Virginia to a misdemeanor count of introducing misbranded drugs
into interstate commerce. The plea came a day after Indivior
said he was stepping down as CEO.

Prosecutors said Thaxter failed to prevent employees from
sharing misleading safety information about the drug with
Massachusetts' Medicaid program as it considered expanding
coverage for it.

Wick Sollers, his attorney, said Thaxter was "unaware of the
alleged misstatements when they were made." Thaxter faces up to
one year in prison when he is sentenced on Sept. 29 and has
agreed to pay $600,000 in fines and forfeitures.

The plea came after Indivior in April 2019 was indicted and
charged with engaging in an illegal scheme to boost
prescriptions of Suboxone in one of the few corporate
prosecutions related to the U.S. opioid addiction
epidemic.

Prosecutors alleged Indivior deceived doctors and healthcare
benefit programs into believing the film version of Suboxone,
which has an opioid component, was safer and less susceptible to
abuse than similar drugs.

The indictment said Indivior also used an internet and
telephone program touted as a resource for opioid addicts to
connect them to doctors it knew were prescribing Suboxone and
other opioids at high rates and in suspect circumstances.

Prosecutors said the scheme began before British consumer
goods company Reckitt Benckiser spun off Indivior.
Reckitt Benckiser last year agreed to pay $1.4 billion to
resolved related claims.

Slough, England-based Indivior denies wrongdoing and is
scheduled to face trial in September. Indivior on Tuesday said
it is working to "resolve outstanding investigations and
litigations as expeditiously as possible."
(Reporting by Nate Raymond in Boston
Editing by Chris Reese and Marguerita Choy)

More News
21 Jul 2020 16:02

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
20 Jul 2020 13:32

Monday broker round-up

(Sharecast News) - British American Tobacco: Jefferies downgrades to hold with a target price of 3,000.0p.

Read more
20 Jul 2020 11:23

Deutsche Bank raises target price on Reckitt Benckiser

(Sharecast News) - Analysts at Deutsche Bank upped their target price on consumer goods company Reckitt Benckiser from 7,400.0p to 8,400.0p on Monday, highlighting the group's "enduring fame".

Read more
20 Jul 2020 09:38

UK BROKER RATINGS SUMMARY: Barclays Downgrades Standard Life Aberdeen

UK BROKER RATINGS SUMMARY: Barclays Downgrades Standard Life Aberdeen

Read more
16 Jul 2020 22:34

Brazilian waste management firm finds cost-cutting users in pandemic

By Tatiana BautzerSAO PAULO, July 16 (Reuters) - A month-old Brazilian company's machines that use bacteria to break down organic waste has found users among domestic upscale supermarket Natural da Terra, units of Reckitt Benckiser and Siemens AG ...

Read more
10 Jul 2020 09:43

UK BROKER RATINGS SUMMARY: Investec Ups Barclays; HSBC Cuts RSA

UK BROKER RATINGS SUMMARY: Investec Ups Barclays; HSBC Cuts RSA

Read more
9 Jul 2020 13:51

Thursday broker round-up

(Sharecast News) - Hargreaves Lansdown: Berenberg reiterates hold with a target price of 1,830.0p.

Read more
9 Jul 2020 09:36

UK BROKER RATINGS SUMMARY: RBC Downgrades Compass To Underperform

UK BROKER RATINGS SUMMARY: RBC Downgrades Compass To Underperform

Read more
6 Jul 2020 09:15

UK BROKER RATINGS SUMMARY: Credit Suisse Downgrades BHP To Neutral

UK BROKER RATINGS SUMMARY: Credit Suisse Downgrades BHP To Neutral

Read more
30 Jun 2020 21:48

UPDATE 1-Former Indivior CEO pleads guilty in U.S. in opioid addiction treatment probe

(Adds further details on case, background on investigation)By Nate RaymondJune 30 (Reuters) - Shaun Thaxter, the former chief executive of drugmaker Indivior Plc, pleaded guilty on Tuesday to a criminal charge arising out of a U.S. Justice Departm...

Read more
30 Jun 2020 14:20

Tuesday broker round-up

(Sharecast News) - Paragon: Canaccord upgrades to buy with a target price of 454.0p.

Read more
30 Jun 2020 09:31

UK BROKER RATINGS SUMMARY: Exane BNP Downgrades RELX To Underperform

UK BROKER RATINGS SUMMARY: Exane BNP Downgrades RELX To Underperform

Read more
29 Jun 2020 13:45

Monday broker round-up

(Sharecast News) - Balfour Beatty: Jefferies downgrades to hold with a target price of 260.0p.

Read more
29 Jun 2020 10:29

Indivior Names Promotes Finance Head Crossley To CEO, Thaxter Departs

Indivior Names Promotes Finance Head Crossley To CEO, Thaxter Departs

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.